中国国际金融股份有限公司 关于苏州东微半导体股份有限公司 差异化权益分派特殊除权除息事项的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为苏州 东微半导体股份有限公司（以下简称"东微半导"或"公司"）首次公开发行股票并 在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所科创板股票上市规则》等相关法律法规和规范性文件的要求，对东微半导 差异化权益分派特殊除权除息的事项进行了核查，具体核查情况如下： 一、本次差异化权益分派的原因 公司分别于 2023 年 9 月 19 日、2023 年 10 月 9 日召开了第一届董事会第十 九次会议、2023 年第二次临时股东大会，审议通过了《关于以集中竞价交易方 式回购公司股份方案的议案》，同意公司以首次公开发行人民币普通股取得的部 分超募资金通过上海证券交易所交易系统以集中竞价交易方式回购公司股票。本 次回购的资金总额不低于人民币2,500万元（含）且不超过人民币5,000万元（含）， 回购价格不超过人民币 140 元/股（含），回购的股份将在未来适宜时机全部用 于股权激励及/或员工持股计划。回购期限为自公司股东大会审 ...

Core Viewpoint - Dongwei Semiconductor (688261), known as the "first stock of charging pile chips," has seen its stock price plummet nearly 80% from a peak of 179.27 yuan to 38.63 yuan due to the downturn in the power semiconductor industry and increased competition [1] Company Performance - Dongwei Semiconductor was established in 2008 and operates as a fabless manufacturer of power semiconductors, with products widely used in various sectors including 5G base stations, data centers, and electric vehicle charging [1] - The company experienced significant growth from 2020 to 2022, with 2022 revenues reaching 1.116 billion yuan and net profits of 284 million yuan, marking year-on-year increases of 42.72% and 93.57%, respectively [4] - However, in 2023, the company reported a revenue decline of 12.86% to 973 million yuan, with net profit dropping over 50% to 140 million yuan [7][8] Competitive Landscape - Dongwei Semiconductor's gross margin has significantly decreased from 33.96% in 2022 to 22.73% in 2023 and further to 14.29% in 2024, indicating a loss of competitive edge compared to peers [8][9] - The company's inventory turnover efficiency has worsened, with inventory turnover days increasing from 56.31 days in 2021 to 146.74 days in 2024, leading to substantial asset impairment losses [11] New Business Development - Despite ongoing R&D investments and attempts to diversify product offerings, new business lines such as Super Silicon MOSFET and SiC devices have contributed minimally to overall revenue, maintaining a combined share of only about 4% from 2021 to 2024 [13][14] - The SiC market is expected to grow significantly, but Dongwei Semiconductor faces challenges due to its lack of technological advantages and the competitive landscape dominated by established players [17][19]

Investment Rating - The report maintains an investment rating of "Outperform" for the biopharmaceutical sector [7]. Core Insights - The PD-(L)1 monoclonal antibody market is vast, with multiple companies developing PD-1 class upgrade products, including PD-1/VEGF bispecific antibodies and PD-1/IL-2 bispecific antibodies. The IBI363 from Innovent Biologics is expected to be the next significant PD-1 upgrade product following the PD-1/VEGF bispecific antibody [2][21]. - IBI363 has shown excellent data in the treatment of wild-type NSCLC and colorectal cancer, indicating its potential to expand into first-line treatment markets based on its performance in the IO resistant market [2][22]. - The competitive landscape for PD-1/IL-2 bispecific antibodies is favorable for IBI363, as it is the only PD-1/IL-2α bispecific antibody currently in Phase II clinical trials, while most competitors are in earlier stages [3][25]. Summary by Sections Weekly New Drug Market Review - From June 2 to June 6, 2025, the top five companies in the new drug sector by stock performance were Junsheng Tai Pharmaceutical-B (24.29%), Zai Lab (23.28%), Innovent Biologics (18.08%), Maiwei Biopharma (17.72%), and Shenzhou Cell (17.24%). The bottom five were Deqi Pharmaceutical-B (-12.68%), JACOB-B (-11.90%), Heptares Therapeutics-B (-10.86%), CanSino Biologics-B (-10.75%), and WuXi AppTec-B (-8.54%) [1][17]. Weekly New Drug Industry Analysis - The report highlights the potential of IBI363 as a next-generation PD-1 upgrade product, with promising data presented at ASCO 2025. The drug is expected to target multiple tumor types and expand into first-line treatment markets [2][21]. Weekly New Drug Approval & Acceptance Status - This week, 20 new drug or new indication applications were approved in China, including drugs from Zai Lab and Shenzhen Xinlitai. Additionally, 11 new drug applications were accepted, including those from MSD and Eli Lilly [4][28]. Weekly New Drug Clinical Application Approval & Acceptance Status - There were 21 new drug clinical application approvals and 43 new drug clinical applications accepted in the domestic market this week [5].

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The stroke treatment market in China is projected to exceed 100 billion yuan, with QHRD106 from Qianhong Pharmaceutical expected to become a major product with potential sales of 4-5 billion yuan [1][19]. - The A-share pharmaceutical index has shown a year-to-date increase of 6.6%, outperforming the CSI 300 index by 9.0% [4][9]. - The report highlights the importance of secondary prevention in acute ischemic stroke (AIS) treatment, emphasizing the need for effective therapies [18][19]. Summary by Sections Industry Trends - The A-share pharmaceutical index has increased by 2.6% this week, with significant gains in various sub-sectors, including chemical drugs (+4.4%) and raw materials (+3.2%) [4][9]. - The H-share biotechnology index has shown a year-to-date increase of 41.4%, outperforming the Hang Seng Technology Index [4][9]. Market Potential - The number of stroke patients in China is approximately 13 million, with an annual increase of about 4.5%-4.8%, indicating a growing market for stroke medications [19][27]. - The report estimates that the sales peak for QHRD106 could reach 4-5 billion yuan by 2027, positioning it as a potential blockbuster drug [1][19]. R&D Progress and Company Dynamics - QHRD106 is currently in clinical phase II, with data expected to be released in the second half of 2025, potentially outperforming existing similar drugs [1][19]. - The report lists several companies to watch, including Qianhong Pharmaceutical, Hengrui Medicine, and BeiGene, focusing on growth potential in the innovative drug sector [10][11]. Investment Strategy - Recommended sub-sector rankings for investment are: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [10]. - Specific stock selection strategies include focusing on growth in innovative drugs and identifying undervalued stocks in traditional Chinese medicine [10].

中国国际金融股份有限公司 关于苏州东微半导体股份有限公司 核心技术人员离职的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为苏州 东微半导体股份有限公司（以下简称"东微半导"或"公司"）首次公开发行股票并 在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所科创板股票上市规则》等相关法律法规和规范性文件的要求，对东微半导 核心技术人员离职的事项进行了核查，具体核查情况如下： 一、核心技术人员离职的具体情况 公司董事会近日收到公司核心技术人员刘磊先生的辞职申请。刘磊先生因个 人职业发展原因，向公司申请辞去核心技术人员职务，辞职后将不再担任公司任 何职务。 （一）刘磊先生的具体情况 刘磊先生在职期间作为核心技术人员参与公司研发工作，目前已完成工作交 接，其离职不会对公司的技术研发、产品创新、核心竞争力与持续经营能力产生 1 不利影响。 刘磊先生在职期间参与研究并申请的专利等知识产权均为职务成果，截至本 核查意见出具之日，该等职务成果所形成的所有权均属于公司，不涉及权利纠纷 或潜在纠纷，其离职不会影响公司专利等知识产权的完整性。 （三）保密及竞业限制情况 根据公 ...

苏州东微半导体股份有限公司 关于公司核心技术人员离职的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688261 证券简称：东微半导 公告编号：2025-023 苏州东微半导体股份有限公司（以下简称"公司"）核心技术人员刘磊 先生因个人职业发展原因向公司申请辞去核心技术人员职务，辞职后将不再担任 公司任何职务。 公司与刘磊先生签有《劳动合同》及《保密、竞业禁止及知识产权归属 协议》等，不存在涉及职务成果、知识产权相关的纠纷或潜在纠纷，其离职不影 响公司专利等知识产权的完整性。 刘磊先生目前已完成工作交接，其离职不会对公司的技术研发、产品创 新、核心竞争力与持续经营能力产生不利影响。 一、 核心技术人员离职的具体情况 公司董事会近日收到公司核心技术人员刘磊先生的辞职申请。刘磊先生因个 人职业发展原因，向公司申请辞去核心技术人员职务，辞职后将不再担任公司任 何职务。公司对刘磊先生任职期间为公司做出的贡献表示衷心感谢！ （一）刘磊先生的具体情况 刘磊，男，1984 年出生，中国国籍，无境外永久居留 ...

Investment Rating - The industry investment rating is "Outperform" (maintained) [2] Core Insights - The profitability of the power semiconductor industry is steadily improving, with the automotive sector and data centers being the main growth drivers. The domestic production of medium and low voltage devices for automobiles is continuously advancing [4][7] - The penetration of SiC MOSFETs in new energy vehicles is increasing, with a notable rise in the market share of domestic suppliers in the IGBT module sector [38][39] - The overall industry is entering a stable phase, with demand from consumption and industrial control maintaining steady growth, while the new energy vehicle market continues to expand [6][21] Summary by Sections Power Semiconductor Performance - The industry is experiencing a recovery in profitability as revenues improve, with automotive and data center applications being the primary growth areas [4] - The sales volume of new energy vehicles in March reached 1.24 million units, a year-on-year increase of 40.1%, with a penetration rate of 42.4% [32][34] New Energy Vehicles - The market share of new energy vehicles with a peak power of over 200kW has increased from 9% in 2022 to 25% in the first quarter of 2025 [35] - The penetration rate of SiC MOSFETs in new energy vehicles reached 18.9% in the first quarter of 2025, indicating a shift towards higher power modules [38] Charging Infrastructure - The number of charging stations in March 2025 increased by 634,000 units, with public charging stations showing a year-on-year decrease of 18.35% [5] Market Dynamics - The competition among leading companies in the IGBT module market is stabilizing, with domestic suppliers gaining market share as overseas competitors decline [38][39] - The industry is expected to continue its growth trend in 2024, driven by the demand for automotive power devices and the ongoing transition to electric vehicles [6][21]

Meeting Overview - The shareholder meeting of Suzhou Dongwei Semiconductor Co., Ltd. was held on May 20, 2025, at the company's conference room in Suzhou [1] - A total of 61 ordinary shareholders attended the meeting, holding 59,224,663 voting rights, which accounts for 49.2753% of the total voting rights [1] Voting Results - All non-cumulative voting proposals were approved during the meeting [1][2] - The voting results for the proposals showed a high level of agreement, with the majority of votes in favor: - Proposal 1: 59,161,676 votes in favor (99.8936%) [1] - Proposal 2: 59,159,856 votes in favor (99.8906%) [1] - Proposal 3: 59,159,438 votes in favor (99.8899%) [1] - Proposal 4: 59,162,576 votes in favor (99.8952%) [2] - Proposal 5: 59,177,459 votes in favor (99.9203%) [3] Legal Compliance - The meeting was convened and conducted in accordance with legal and regulatory requirements, as confirmed by the attending lawyers [4]

证券代码：688261 证券简称：东微半导 公告编号：2025-022 苏州东微半导体股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 20 日 （二） 股东大会召开的地点：江苏省苏州市工业园区金鸡湖大道 99 号纳米城东 南区 65 栋苏州东微半导体股份有限公司会议室 2、 公司在任监事3人，现场结合通讯方式出席3人； （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 61 | | --- | --- | | 普通股股东人数 | 61 | | 2、出席会议的股东所持有的表决权数量 | 59,224,663 | | 普通股股东所持有表决权数量 | 59,224,663 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 49.2753 | | 例（%） | | ...

浙江天册律师事务所 关 于 苏州东微半导体股份有限公司 2024 年年度股东大会的 法律意见书 〒天册律师事务所 杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 电话：+86 571 8790 1110 传真: + 86 571 8790 1500 www.tclawfirm.com 一 天册律师事: 法律意见书 浙江天册律师事务所 关于苏州东微半导体股份有限公司 2024 年年度股东大会的 法律意见书 编号:TCYJS2025H0763 号 致:苏州东微半导体股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国 证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称"《股东会 规则》")等法律、法规和规范性文件,以及《苏州东微半导体股份有限公司章程》 (以下简称"《公司章程》")的有关规定,浙江天册律师事务所(特殊普通合伙) (以下简称"本所")接受苏州东微半导体股份有限公司(以下简称"东微半导" 或"公司")委托,指派律师参加东微半导 2024年年度股东大会。 本法律意见书仅供东微半导 2024年年度股东大会之目的使用。本所律师同 意将本法律意见书随东微 ...